Related references
Note: Only part of the references are listed.In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
P. H. Lizotte et al.
NATURE NANOTECHNOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes
Yaqing Qie et al.
SCIENTIFIC REPORTS (2016)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
Mingye Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Michael Kalos et al.
IMMUNITY (2013)
Targeting of Antigens to B Lymphocytes via CD19 as a Means for Tumor Vaccine Development
Yunfeng Ma et al.
JOURNAL OF IMMUNOLOGY (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
Gene-engineered T cells for cancer therapy
Michael H. Kershaw et al.
NATURE REVIEWS CANCER (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adoptive immunotherapy for cancer: harnessing the T cell response
Nicholas P. Restifo et al.
NATURE REVIEWS IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy
Nam-Hyuk Cho et al.
NATURE NANOTECHNOLOGY (2011)
Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response
Haiyan Li et al.
NATURE NANOTECHNOLOGY (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Dendritic cell-based therapeutic cancer vaccines: what we have and what we need
Pawel Kalinski et al.
FUTURE ONCOLOGY (2009)
Immunogenic and tolerogenic cell death
Douglas R. Green et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Nanoparticle-mediated cellular response is size-dependent
Wen Jiang et al.
NATURE NANOTECHNOLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Design and characterization of lysine cross-linked mereapto-acid biocompatible quantum dots
W Jiang et al.
CHEMISTRY OF MATERIALS (2006)
Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte
SJ Gardai et al.
CELL (2005)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Cancer immunotherapy: A treatment for the masses
JN Blattman et al.
SCIENCE (2004)
Share Paper
